ECBF invests in its 8th portfolio company, Biosyntia ApS from Denmark. Biosyntia is a precision fermentation company focused on replacing a fossil-based production process with a bio-based process for products such as vitamins and other ingredients. ECBF joins Novo Seeds and Sofinnova Partners in the shareholder structure and leads the current round of €11.5m.

Biosyntia intends to use the Series B investment to both expand its product range and start the production phase of its sustainably produced nutritional ingredients. The first product to be marketed is a bio-based biotin (vitamin B7) that can be used in food supplements, food and beauty products. “Our team is truly proud of the recognition this investment gives. The investment enables us to finally offer customers the first and only natural and sustainable alternative to what is available for them today”, says Martin Plambech, CEO of Biosyntia. “With ECBF joining Sofinnova Partners and Novo Seeds as investors, we improve an already strong investor base. Combined with our promising pipeline of ingredients, we are in the making of a new, global fermentation-based ingredient producer that can challenge today’s incumbents,” he continues.

For ECBF which operational headquarter is in Bonn, Germany, while the legal body is residing in Luxembourg, it is the 8th investment in a row. Just in February this year the final closing of the fund with €300m has been announced.